📖 New Online: "#AI in #LungCancer Clinical Translation" — a collaborative effort between my group Dr. Erjia (EJ) Zhu @ErjiaZ96533 and Dr. @JiaWu_PhD. We share insights through the lens of thoracic oncologists navigating this evolving landscape. 🔗 .👉

Thank you @DAVAOnc @vinayjai for another successful Lung Summit meeting! Nice to hangout and exchange scientific ideas in the beautiful island Kona with Drs. Jay Zhang, Haniel Araujo, @FSkoulidis, John Heymach, Jia Wu, @lungoncdoc @MDAndersonNews. Amazing nature.

RT @jennifermarksmd: Very important study planned by Dr. @LeXiuning :A phase I/lb study of concurrent intrathecal and intravenous amivantam….

I am extremely thankful for the entire RAMOSE trial team, co-investigators, @hoosiercancer HCRN , clinical research staff, and pts/families to complete this large multi-center randomized investigator-initiated trial (IIT) in #EGFR #lungcancer. We will report OS and other.

We have three TKIs: firmonertinib, sunvozertinib, and zipalertinib, with FDA breakthrough designation (BTD) for EGFR Ex20ins NSCLC patients. We will change the SoC landscape soon for this patient population! @EGFRResisters @Exon20Group @lungoncdoc I cannot wait to debate among.

It is such a treat to discuss science with thoracic colleagues in the beautiful island of Kona, Hawaii. @lungoncdoc @jennifermarksmd @OncoViews @oncodaily @MDAndersonNews.

💐💐💐Congratulations, Dr. @KelseyPanMD, on your graduation from the #Hematology/#Oncology Fellowship at MDACC @MDAndersonNews.It’s been a pleasure working with you, and I’m truly excited to now call you a fellow thoracic oncologist. I look forward to collaborating with you on

❤️ ✈️ Feeling hopeful and joyful as I leave Chicago after a productive but exhausting #ASCO25 . 💐 🎊 On the final evening, we celebrated the 10-year anniversary of #osimertinib approval—an incredible milestone—surrounded by friends and colleagues from around the world. I'm

#ASCO25 with friends and colleagues from academia and industry, from all parts of the globe, during #lungcancer poster session. @HHorinouchi @geoff_oxnard @LaurenByersMD @MDAndersonNews Drs. TimYap, MartinReck, MolliLi AlexSpira.

BAY88 has its name now, sevabertinib 😀. We are actively enrolling globally for HER2-activating mutation treatment-naive NSCLC patients.

BN-39643 represents the newest concept of EGFR TKI, higher potency than osimertinib, CNS penetration, covering classical, C797S, PACC, and ex20 mutations, so it prevents all EGFR dependent resistance.

NVL-330 represents the next generation of HER2 TKI. High CNS penetration, high potency, sparing EGFR wt.

#AACR25, Dr. Simon Heek presented "Association of baseline ctDNA #EGFR mutation detection with clinical outcome in the phase II RAMOSE trial assessing ramucirumab plus osimertinibversus osimertinibin EGFR+ #LungCancer. @MDAndersonNews @lungoncdoc .👉Baseline assessment of #EGFR

#AACR25 is always a great place to share our passion for #CancerResearch, catch up on the latest breakthroughs, and spark new ideas. I had a great time connecting with fellow researchers and friends in the field. @DavidHongMD @lungoncdoc @MDAndersonNews @danieltanmd

For your dedication for patient care, clinical research, education, and for your global influence as an APAC lung cancer leader, I support you, my friend! @HHorinouchi @IASLC.